SUVRETTA CAPITAL MANAGEMENT, LLC 13D and 13G filings for Mereo BioPharma Group plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:18 pm Sale |
2024-09-30 | 13G | Mereo BioPharma Group plc MREO |
SUVRETTA CAPITAL MANAGEMENT, LLC | 0 0.000% |
-36,854,190 (Position Closed) |
Filing |
| 2024-02-13 5:26 pm Purchase |
2023-12-31 | 13G | Mereo BioPharma Group plc MREO |
SUVRETTA CAPITAL MANAGEMENT, LLC | 36,854,190 5.300% |
32,000 (+0.09%) |
Filing |
| 2023-02-13 1:21 pm Sale |
2022-12-31 | 13G | Mereo BioPharma Group plc MREO |
SUVRETTA CAPITAL MANAGEMENT, LLC | 36,822,190 5.900% |
-8,888,145 (-19.44%) |
Filing |
| 2022-02-11 4:37 pm Purchase |
2021-12-31 | 13G | Mereo BioPharma Group plc MREO |
SUVRETTA CAPITAL MANAGEMENT, LLC | 45,710,335 8.400% |
13,882,835 (+43.62%) |
Filing |
| 2021-02-19 4:27 pm Purchase |
2021-02-10 | 13G | Mereo BioPharma Group plc MREO |
SUVRETTA CAPITAL MANAGEMENT, LLC | 31,827,500 5.900% |
31,827,500 (New Position) |
Filing |